← Search & browse all drugs

drospirenone

G03AC10

Forms & Strengths

Oral tablets: 3 mg

Adult Dosing

Contraception: 3 mg orally once daily, taken continuously without a pill-free interval
Premenstrual dysphoric disorder (PMDD): 3 mg orally once daily with ethinyl estradiol combination
Moderate acne vulgaris: 3 mg orally once daily with ethinyl estradiol combination in females at least 14 years of age

Pediatric Dosing

Post-menarcheal adolescents (at least 14 years): 3 mg orally once daily for contraception, PMDD, or acne (as combination product)

Indications

Prevention of pregnancy
Treatment of symptoms of premenstrual dysphoric disorder (PMDD)
Treatment of moderate acne vulgaris in females at least 14 years old

Mechanism of Action

Synthetic progestin with antimineralocorticoid and antiandrogenic activity
Suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to inhibit ovulation
Increases cervical mucus viscosity to prevent sperm penetration
Alters endometrium to reduce implantation probability

Contraindications

Renal impairment
Hepatic dysfunction or disease
Adrenal insufficiency
Known or suspected high risk of arterial or venous thrombotic diseases
Known or suspected carcinoma of the breast or other progestin-sensitive cancer
Undiagnosed abnormal uterine bleeding

Adverse Reactions

Hyperkalemia
Menstrual irregularities (spotting, breakthrough bleeding, amenorrhea)
Headache and migraine
Nausea and vomiting
Breast tenderness
Weight gain
Mood changes and depression
Venous thromboembolism

Drug Interactions

Potassium-sparing diuretics, ACE inhibitors, ARBs, aldosterone antagonists, NSAIDs: increased risk of hyperkalemia
CYP3A4 inducers (e.g., rifampin, St. John's wort, carbamazepine): decreased drospirenone efficacy
CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increased plasma concentrations of drospirenone

Curated Content: Needs Vetting Before Put to Clinical Use